Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors

Conditions:   Lung Cancer Squamous Cell;   Solid Tumors;   Head & Neck Cancer;   Pancreatic Cancer
Interventions:   Drug: Palbociclib;   Drug: Gedatolisib
Sponsors:   Dana-Farber Cancer Institute;   Pfizer
Not yet recruiting - verified February 2017

http://ift.tt/2lOoqNA